A Phase IIa, Double-Blind, Randomized, Intracohort Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101 in Patients with Diffuse Cutaneous Systemic Sclerosis
|Effective start/end date||10/6/20 → 10/31/25|
- EMERALD HEALTH PHARMACEUTICALS, INC
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.